FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ useMerck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use Share XFDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ usehttps://pharmaphorum.com/news/fda-reviews-merck-cos-keytruda-in-new-tumour-agnostic-use/
BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
BMS/AbbVie’s combo falls short in untreated multiple myeloma trialAdding Bristol-Myers Squibb/AbbVie’s Empliciti to Revlimid, developed by BMS’ recently acquired Celgene unit, does not improve survival in Share XBMS/AbbVie’s combo falls short in untreated multiple myeloma trialhttps://pharmaphorum.com/news/bms-abbvies-combo-falls-short-in-untreated-multiple-myeloma-trial/
BMS joins with Voluntis to create cancer support appBristol-Myers Squibb has joined with digital therapeutics firm Voluntis to create an app that will support cancer patients. Share XBMS joins with Voluntis to create cancer support apphttps://pharmaphorum.com/news/bms-joins-with-voluntis-to-create-cancer-support-app/
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
Gilead poaches oncology expert Quigley from BMSGilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of Share XGilead poaches oncology expert Quigley from BMShttps://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
